ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security
Holders.

On June1, 2017, the Company held its 2017 Annual Meeting of
Stockholders (the Annual Meeting) at the offices of Dorsey
Whitney LLP in Minneapolis, Minnesota. Dan W. Gladney, Chairman
of the Board of Directors of the Company, presided. At the Annual
Meeting, the Companys stockholders approved each of the following
proposals set forth in the Companys Definitive Proxy Statement on
Schedule 14A, which was filed with the Securities and Exchange
Commission and mailed to stockholders on April27, 2017:

Proposal 1:

The Companys stockholders elected two ClassI directors to hold
office until the 2020 annual meeting and until the directors
successor is elected and qualified, or, if sooner, until the
directors death, resignation or removal.

Based on the following results of voting, each of the ClassI
directors was re-elected:

Proposal 2:

The Companys stockholders voted on a non-binding advisory
resolution approving the compensation of the Companys Named
Executive Officers, as set forth below:

Proposal 3:

The Companys stockholders ratified the appointment of Deloitte
Touche LLP as the Companys independent registered public
accountants for the year ending December31, 2016, as set forth
below:

About ENTEROMEDICS INC. (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.